OpGen, Inc. (NASDAQ:OPGN – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.66 and traded as low as $2.52. OpGen shares last traded at $2.58, with a volume of 4,941 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on OpGen in a report on Saturday, May 25th. They set a “sell” rating for the company.
Read Our Latest Stock Analysis on OpGen
OpGen Stock Up 2.0 %
Hedge Funds Weigh In On OpGen
An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new stake in OpGen, Inc. (NASDAQ:OPGN – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen at the end of the most recent reporting period. Institutional investors and hedge funds own 2.68% of the company’s stock.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Recommended Stories
- Five stocks we like better than OpGen
- Health Care Stocks Explained: Why You Might Want to Invest
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Euro STOXX 50 Index?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.